Protalix BioTherapeutics, Inc. (PLX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Protalix BioTherapeutics reported revenue of $52.7M, down 1.2% from $53.4M the year before. Net income was -$6.6M (a -12.5% net margin), or -$0.08 per diluted share. Gross margin was 48.8% and operating margin was -10.4%. Operating activities generated -$12.0M of cash, leaving -$13.6M of free cash flow. At fiscal year end, Protalix BioTherapeutics held $82.3M in total assets against $34.1M in total liabilities, including $14.7M of cash and equivalents.
Open the full interactive Protalix BioTherapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Protalix BioTherapeutics Key Stats
| Share Price | $2.75 |
|---|---|
| Market Cap | $227.0M |
| Revenue YoY Growth | -1.2% |
| 52-Week Range | $1.67 – $3.15 |
| Shares Outstanding | 80.0 million (basic, 2026 Q2) |
Protalix BioTherapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $62.9M | $38.4M | $47.6M | $65.5M | $53.4M | $52.7M |
| Gross Profit | $52.0M | $22.0M | $28.0M | $42.5M | $29.1M | $25.8M |
| Operating Income | $2.7M | -$20.5M | -$13.0M | $10.5M | $3.9M | -$5.5M |
| Pre-Tax Income | -$6.5M | -$27.6M | -$14.4M | $8.6M | $4.2M | -$5.6M |
| Income Tax | — | — | $530,000 | $254,000 | $1.2M | $996,000 |
| Net Income | -$6.5M | -$27.6M | -$14.9M | $8.3M | $2.9M | -$6.6M |
| Diluted EPS | -$0.22 | -$0.62 | -$0.31 | $0.09 | $0.04 | -$0.08 |
Protalix BioTherapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $17.9M | $9.1M | $33.8M | $19.9M |
| Net Income | $2.4M | -$5.5M | $18.3M | $3.8M |
| Diluted EPS | $0.03 | -$0.07 | $0.22 | $0.05 |
Protalix BioTherapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.3M | $39.0M | $17.1M | $23.6M | $19.8M | $14.7M |
| Current Assets | $55.7M | $61.7M | $44.9M | $69.9M | $60.1M | $66.7M |
| Total Assets | $67.9M | $73.7M | $55.8M | $84.4M | $73.4M | $82.3M |
| Current Liabilities | $86.5M | $33.2M | $32.4M | $45.5M | $25.6M | $26.5M |
| Total Long-Term Debt | — | $27.9M | $28.2M | — | — | — |
| Total Liabilities | $95.0M | $79.7M | $66.4M | $50.9M | $30.2M | $34.1M |
| Shareholders' Equity | -$27.0M | -$6.0M | -$10.6M | $33.6M | $43.2M | $48.2M |
Protalix BioTherapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$26.1M | -$10.3M | -$25.0M | -$1.3M | $8.7M | -$12.0M |
| Cash From Investing | -$20.0M | $18.9M | -$5.0M | -$16.7M | $4.2M | -$2.4M |
| Cash From Financing | $46.5M | $12.1M | $8.2M | $24.7M | -$16.8M | $9.3M |
| Free Cash Flow | -$26.8M | -$11.7M | -$25.6M | -$2.5M | $7.4M | -$13.6M |
Figures from Protalix BioTherapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Protalix BioTherapeutics financials page for every line item.
Protalix BioTherapeutics Company Profile
| Ticker | PLX |
|---|---|
| Exchange | NYSE |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Hackensack, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001006281 |
Frequently Asked Questions
What was Protalix BioTherapeutics' revenue in fiscal 2025?
Protalix BioTherapeutics (PLX) reported revenue of $52.7M for fiscal 2025.
What is Protalix BioTherapeutics' annual revenue history?
Protalix BioTherapeutics' annual revenue by fiscal year: 2020: $62.9M; 2021: $38.4M; 2022: $47.6M; 2023: $65.5M; 2024: $53.4M; 2025: $52.7M.
What was Protalix BioTherapeutics' net income in fiscal 2025?
Protalix BioTherapeutics reported net income of -$6.6M for fiscal 2025.
What was Protalix BioTherapeutics' earnings per share (EPS) in fiscal 2025?
Protalix BioTherapeutics' diluted EPS was -$0.08 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Protalix BioTherapeutics generate in fiscal 2025?
Protalix BioTherapeutics generated -$13.6M of free cash flow in fiscal 2025.
What was Protalix BioTherapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Protalix BioTherapeutics reported revenue of $19.9M.
How many shares of Protalix BioTherapeutics are outstanding?
Protalix BioTherapeutics reported a weighted average of 80.0 million basic shares outstanding in 2026 Q2.
What is Protalix BioTherapeutics' market cap?
Based on its latest closing price, Protalix BioTherapeutics (PLX) has a market capitalization of about $227.0M.
When does Protalix BioTherapeutics' fiscal year end?
Protalix BioTherapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Protalix BioTherapeutics headquartered?
Protalix BioTherapeutics lists its business address in Hackensack, New Jersey in its SEC filings.
Protalix BioTherapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →